Skip to main content
SpringerLink
Log in

Reply by L. Maffioli

  • Reply
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–13.

    Article  CAS  PubMed  Google Scholar 

  2. Kuroda I. Strontium-89 for prostate cancer with bone metastases: the potential of cancer control and improvement of overall survival. Ann Nucl Med. 2014;28:11–6.

    Article  CAS  PubMed  Google Scholar 

  3. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer Clin Oncol. 1991;9:1084–6.

    Article  Google Scholar 

  4. Biersack H-J, Palmedo H, Andris A, et al. Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med. 2011;52:1721–6.

    Article  CAS  PubMed  Google Scholar 

  5. Tu S-M, Millikan RE, Mengistu B, et al. Bone targeted therapy for advanced androgen-indipendent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357:336–41.

    Article  CAS  PubMed  Google Scholar 

  6. Ricci S, Boni G, Pastina I, et al. Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:1023–30.

    Article  CAS  PubMed  Google Scholar 

  7. Zlotta AR, Schulman CC. Can survival be prolonged for patients with hormone-resistant prostate cancer? Lancet. 2001;357:326–7 (Commentary).

    Article  CAS  PubMed  Google Scholar 

  8. Maini CL, Bergomi S, Romano L, Sciuto R. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31 Suppl 1:171–8.

    Article  Google Scholar 

  9. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate cancer: a phase I/II trial. J Nucl Med. 1993;34:1839–44.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Department, A.S.S.T. Ovest Milanese, Via Papa Giovanni Paolo II, Legnano, Milan, 20025, Italy

    Lorenzo Maffioli & Luca Dellavedova

  2. Nuclear Medicine Department, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, Milano, 20122, Italy

    Luigia Florimonte

Authors
  1. Lorenzo Maffioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Dellavedova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luigia Florimonte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lorenzo Maffioli.

Additional information

This reply refers to the letter to the editor at doi:10.1007/s00259-016-3574-3.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maffioli, L., Dellavedova, L. & Florimonte, L. Reply by L. Maffioli. Eur J Nucl Med Mol Imaging 44, 730–731 (2017). https://doi.org/10.1007/s00259-016-3570-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-016-3570-7

Keywords

Search

Navigation